Protalix Biotherapeutics Inc
$ 2.09
1.95%
12 Jun - close price
- Market Cap 168,395,000 USD
- Current Price $ 2.09
- High / Low $ 2.11 / 2.06
- Stock P/E 11.00
- Book Value 0.83
- EPS 0.19
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.14 %
- ROE 0.27 %
- 52 Week High 3.19
- 52 Week Low 1.32
About
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, the rest of Latin America and internationally. The company is headquartered in Karmiel, Israel.
Analyst Target Price
$11.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-18 | 2025-11-13 | 2025-08-14 | 2025-05-09 | 2025-03-17 | 2024-11-14 | 2024-08-14 | 2024-05-10 | 2024-03-14 | 2023-11-06 | 2023-08-07 |
| Reported EPS | 0.22 | -0.07 | 0.03 | -0.04 | -0.05 | 0.09 | 0.03 | -0.03 | -0.06 | -0.07 | -0.03 | 0.21 |
| Estimated EPS | -0.01 | 0.035 | 0.06 | 0.03 | 0.08 | 0.07 | 0.06 | 0.02 | -0.02 | -0.03 | -0.07 | -0.04 |
| Surprise | 0.23 | -0.105 | -0.03 | -0.07 | -0.13 | 0.02 | -0.03 | -0.05 | -0.04 | -0.04 | 0.04 | 0.25 |
| Surprise Percentage | 2300% | -300% | -50% | -233.3333% | -162.5% | 28.5714% | -50% | -250% | -200% | -133.3333% | 57.1429% | 625% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.03 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PLX
2026-06-05 07:40:16
Protalix BioTherapeutics' analysts have maintained an $11.00 price target despite mixed expectations for revenue and profit margins. The company reaffirmed its 2026 revenue guidance of US$78.0 million to US$83.0 million, including a US$25.0 million milestone payment, and received European Commission approval for a new 2 mg/kg every 4 weeks dosing regimen for Elfabrio, triggering another US$25 million payment. Valuation adjustments include a slight decrease in the discount rate but significant shifts in revenue growth, profit margin, and future P/E assumptions.
2026-05-27 17:40:26
H.C. Wainwright has reiterated its Buy rating for Protalix Biotherapeutics (PLX.US) and maintained its target price at $12. This indicates a continued positive outlook from the firm regarding the company's stock performance.
2026-05-21 11:10:56
Protalix BioTherapeutics (PLX) announced it posted a new corporate presentation dated May 2026 on its website, furnished as Exhibit 99.1 in a Form 8-K filing. The presentation highlights the company's financial strength with $33.8M in Q1 2026 revenue and $51.1M cash, a growing pipeline including PRX-115 for uncontrolled gout in Phase 2, and the commercial success of Elfabrio for Fabry disease and Elelyso for Gaucher disease. Key upcoming milestones include expanding Elfabrio's geographic approvals and topline results for the PRX-115 Phase 2 trial in 2H 2027.
2026-05-14 23:10:56
Protalix BioTherapeutics announced its First Quarter 2026 financial and business results. This information was released via a press release from Quantisnow, a real-time market data platform. Quantisnow Plus members were alerted to this publication shortly after its release.
2026-05-14 22:41:40
Protalix BioTherapeutics reported its first-quarter 2026 financial and business results, highlighted by $25 million milestone payment from Chiesi following European Commission approval of Elfabrio's 2 mg/kg every-4-weeks dosing regimen. The company affirmed its 2026 revenue guidance of $78.0 – $83.0 million and noted positive momentum in its commercial execution and advancement of the PRX–115 Phase 2 study for uncontrolled gout, with top-line results expected in the second half of 2027. Protalix ended the quarter with $51 million in cash, cash equivalents, and short-term bank deposits, sufficient to fund ongoing operations.
2026-05-14 12:10:15
Protalix BioTherapeutics reported strong Q1 2026 results, driven by a $25 million milestone payment from Chiesi following European approval of Elfabrio's every four-week dosing regimen. The company reaffirmed its 2026 revenue guidance of $78 million to $83 million and aims for Elfabrio to achieve 15-20% global Fabry market share by 2031. Protalix is well-capitalized with $51 million in cash and continues advancing its PRX-115 Phase II study for uncontrolled gout.
